Cargando…

Serum autotaxin levels in chronic disease and acute exacerbation of fibrosing interstitial lung disease

BACKGROUND: Autotaxin (ATX) is an ecto-enzyme that catalyses the hydrolysis of lysophospholipids to the lipid mediator lysophosphatidic acid (LPA). LPA/ATX signalling has emerged as a new therapeutic target for pulmonary fibrosis; however, the serum levels and dynamics of ATX during the clinical cou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isshiki, Takuma, Shimizu, Hiroshige, Sakamoto, Susumu, Yamasaki, Akira, Miyoshi, Shion, Nakamura, Yasuhiko, Homma, Sakae, Kishi, Kazuma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995540/ https://www.ncbi.nlm.nih.gov/pubmed/35415191 http://dx.doi.org/10.1183/23120541.00683-2021

Ejemplares similares

Association of rs3750920 polymorphism in TOLLIP with clinical characteristics of fibrosing interstitial lung diseases in Japanese
por: Isshiki, Takuma, et al.
Publicado: (2021)

Association of serum high-mobility group box protein 1 level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
por: Shimizu, Hiroshige, et al.
Publicado: (2018)

Association of serum monomeric periostin level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
por: Shimizu, Hiroshige, et al.
Publicado: (2021)

Outcomes and prognosis of progressive pulmonary fibrosis in patients with antineutrophil cytoplasmic antibody-positive interstitial lung disease
por: Sakamoto, Susumu, et al.
Publicado: (2023)

The Activities of Daily Living after an Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Koyama, Kazuya, et al.
Publicado: (2017)

New risk scoring system for predicting 3-month mortality after acute exacerbation of idiopathic pulmonary fibrosis
por: Sakamoto, Susumu, et al.
Publicado: (2022)

Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Isshiki, Takuma, et al.
Publicado: (2019)

Acute exacerbations of progressive-fibrosing interstitial lung diseases
por: Kolb, Martin, et al.
Publicado: (2018)

Role of imaging in progressive-fibrosing interstitial lung diseases
por: Walsh, Simon L.F., et al.
Publicado: (2018)

Impact of accurate diagnosis of interstitial lung diseases on postoperative outcomes in lung cancer
por: Azuma, Yoko, et al.
Publicado: (2022)

Immunohistochemical Detection of Propionibacterium acnes in Granulomas for Differentiating Sarcoidosis from Other Granulomatous Diseases Utilizing an Automated System with a Commercially Available PAB Antibody
por: Isshiki, Takuma, et al.
Publicado: (2021)

Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan
por: Urushiyama, Hirokazu, et al.
Publicado: (2022)

Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia
por: Sugino, Keishi, et al.
Publicado: (2021)

Clinical importance of long non-coding RNA LINC00460 expression in EGFR-mutant lung adenocarcinoma
por: Nakano, Yuta, et al.
Publicado: (2019)

Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases
por: Salonen, Johanna, et al.
Publicado: (2020)

Progression of fibrosing interstitial lung disease
por: Wong, Alyson W., et al.
Publicado: (2020)

Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019)

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
por: Isshiki, Takuma, et al.
Publicado: (2018)

The Burden of Progressive-Fibrosing Interstitial Lung Diseases
por: Cottin, Vincent, et al.
Publicado: (2022)

Management of patients with fibrosing interstitial lung diseases
por: Morrow, Lee E, et al.
Publicado: (2021)

Fibrosing interstitial lung diseases: knowns and unknowns
por: Cottin, Vincent, et al.
Publicado: (2019)

Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study
por: Cao, Mengshu, et al.
Publicado: (2019)

Monocyte count and the risk for acute exacerbation of fibrosing interstitial lung disease: A retrospective cohort study
por: Kawamura, Kodai, et al.
Publicado: (2020)

Elective lung resection after treatment for COVID-19 pneumonia
por: Sakai, Takashi, et al.
Publicado: (2021)

Efficacy of three sputum specimens for the diagnosis of Mycobacterium avium complex pulmonary disease
por: Urabe, Naohisa, et al.
Publicado: (2023)

The natural history of progressive fibrosing interstitial lung diseases
por: Kolb, Martin, et al.
Publicado: (2019)

The natural history of progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2020)

Management and support of patients with fibrosing interstitial lung diseases
por: Barbera, Tyonn, et al.
Publicado: (2021)

Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases
por: Chen, Xianqiu, et al.
Publicado: (2021)

The Role of Radiology in Progressive Fibrosing Interstitial Lung Disease
por: Abu Qubo, Ahmad, et al.
Publicado: (2022)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Burden of illness in progressive fibrosing interstitial lung disease
por: Singer, David, et al.
Publicado: (2022)

Exophiala dermatitidis pneumonia with bronchiectasis required prolonged voriconazole treatment
por: Sekiguchi, Ryo, et al.
Publicado: (2021)

Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan
por: Minegishi, Yuji, et al.
Publicado: (2020)

Development of Propionibacterium acnes-associated Sarcoidosis During Etanercept Therapy
por: Isshiki, Takuma, et al.
Publicado: (2019)

Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
por: Cottin, Vincent
Publicado: (2019)

Diffuse pulmonary ossification associated with fibrosing interstitial lung disease
por: Alami, Badreeddine, et al.
Publicado: (2019)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
por: Kwon, Byoung Soo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_of34t706olr7a2buhldurouqok